Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2008

01.08.2008 | Laboratory Research

High Histone Deacetylase 7 (HDAC7) Expression Is Significantly Associated with Adenocarcinomas of the Pancreas

verfasst von: Mehdi Ouaïssi, MD, Igor Sielezneff, MD, Ricardo Silvestre, PhD, Bernard Sastre, MD, Jean-Paul Bernard, MD, PhD, Joelle Simony Lafontaine, MD, PhD, Marie José Payan, MD, PhD, Laetitia Dahan, MD, Nicolas Pirrò, MD, Jean François Seitz, MD, PhD, Eric Mas, PhD, Dominique Lombardo, PhD, Ali Ouaissi, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Alterations in HDACs gene expression have been reported in a number of human cancers. No information is available concerning the status of HDACs in pancreatic cancer tumors. The aim of the present study was to evaluate the expression levels of members of class I (HDAC1, 2,, 3), class II (HDAC4, 5, 6, and 7), and class III (SIRT1, 2, 3, 4, 5, and 6) in a set of surgically resected pancreatic tissues.

Methods

Total RNA was isolated from 11 pancreatic adenocarcinomas (PA): stage 0 (n = 1), IB (n = 1), IIB (n = 6), III (n = 1), IV (n = 2), one serous cystadenoma (SC), one intraductal papillary mucinous tumor of the pancreas (IMPN), one complicating chronic pancreatitis (CP), and normal pancreas (NP) obtained during donor liver transplantation. Moreover, six other control pancreatic were included. HDACs gene expression was conducted using quantitative real-time polymerase chain reaction (qPCR). Protein expression levels were analyzed by Western blot and their localization by immunohistochemistry analyses of cancer tissues sections.

Results

Remarkably, 9 of the 11 PA (approximately 81%) showed significant increase of HDAC7 mRNA levels. In contrast to PA samples, message for HDAC7 was reduced in CP, SC, and IMPN specimens. The Western blot analysis showed increased expression of HDAC7 protein in 9 out of 11 PA samples, in agreement with the qPCR data. Most of the PA tissue sections examined showed intense labeling in the cytoplasm when reacted against antibodies to HDAC7.

Conclusion

The data showed alteration of HDACs gene expression in pancreatic cancer. Increased expression of HDAC7 discriminates PA from other pancreatic tumors.
Literatur
1.
Zurück zum Zitat Greenlee RT, Murray T, Bolden S, et al. Cancer statistics. Cancer J Clin 2000; 50:7–33.CrossRef Greenlee RT, Murray T, Bolden S, et al. Cancer statistics. Cancer J Clin 2000; 50:7–33.CrossRef
2.
Zurück zum Zitat Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000; 74:243–8.PubMedCrossRef Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000; 74:243–8.PubMedCrossRef
3.
4.
Zurück zum Zitat Gerdes B, Ramaswamy A, Ziegler A, et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer. Ann Surg 2002; 235:51–9.PubMedCrossRef Gerdes B, Ramaswamy A, Ziegler A, et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer. Ann Surg 2002; 235:51–9.PubMedCrossRef
5.
Zurück zum Zitat Cress WD, Seto E. Histone deacetylase, transcriptional control and cancer. J Cell Physiol 2000; 184:1–16.PubMedCrossRef Cress WD, Seto E. Histone deacetylase, transcriptional control and cancer. J Cell Physiol 2000; 184:1–16.PubMedCrossRef
6.
8.
Zurück zum Zitat Amunziato AT, Hansen JC. Role of histone acetylation in the assembly and modulation of chromatin structures. Gene Expr 2000; 9:37–61. Amunziato AT, Hansen JC. Role of histone acetylation in the assembly and modulation of chromatin structures. Gene Expr 2000; 9:37–61.
9.
Zurück zum Zitat Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769–84.PubMedCrossRef Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769–84.PubMedCrossRef
10.
Zurück zum Zitat Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000; 273:793–8.PubMedCrossRef Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000; 273:793–8.PubMedCrossRef
11.
Zurück zum Zitat De Nigris F, Cerutti J, Morelli C, et al. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 2002; 86:917–23.PubMedCrossRef De Nigris F, Cerutti J, Morelli C, et al. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 2002; 86:917–23.PubMedCrossRef
12.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Handbook, 6th edition. American Joint Committee on Cancer. New York: Springer Verlag, 2002 Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Handbook, 6th edition. American Joint Committee on Cancer. New York: Springer Verlag, 2002
13.
Zurück zum Zitat Corpet F. Multiple sequence alignment with hierarchical clustering. Nucl Acids Res 1988; 22:10881–90.CrossRef Corpet F. Multiple sequence alignment with hierarchical clustering. Nucl Acids Res 1988; 22:10881–90.CrossRef
14.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 2001; 25:402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 2001; 25:402–8.PubMedCrossRef
15.
Zurück zum Zitat Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Inv 2007; 117:659–71.CrossRef Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Inv 2007; 117:659–71.CrossRef
16.
Zurück zum Zitat Shen S, Li J, Casaccia-Bonnefil P. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing brain. J Cell Biol 2005; 169:577–88.PubMedCrossRef Shen S, Li J, Casaccia-Bonnefil P. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing brain. J Cell Biol 2005; 169:577–88.PubMedCrossRef
17.
Zurück zum Zitat Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene 1996; 13:1819–30.PubMed Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene 1996; 13:1819–30.PubMed
18.
Zurück zum Zitat Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001; 20:7437–46.PubMedCrossRef Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001; 20:7437–46.PubMedCrossRef
19.
20.
Zurück zum Zitat Rosty C, Goggind M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002; 16:37–52.PubMedCrossRef Rosty C, Goggind M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002; 16:37–52.PubMedCrossRef
21.
Zurück zum Zitat Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141–9.PubMedCrossRef Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141–9.PubMedCrossRef
22.
Zurück zum Zitat Iacobuzio-Donahue CA, Ashfaq A, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63:8614–22.PubMed Iacobuzio-Donahue CA, Ashfaq A, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63:8614–22.PubMed
23.
Zurück zum Zitat Bardeey N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2:897–909.CrossRef Bardeey N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2:897–909.CrossRef
24.
Zurück zum Zitat Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, et al. Molecular alterations in pancreatic carcinoma expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 2003; 201:63–74.PubMedCrossRef Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, et al. Molecular alterations in pancreatic carcinoma expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 2003; 201:63–74.PubMedCrossRef
25.
Zurück zum Zitat Shekouh A, Thompson CC, Prime W, et al. Development and application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003; 3:1988–2001.PubMedCrossRef Shekouh A, Thompson CC, Prime W, et al. Development and application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003; 3:1988–2001.PubMedCrossRef
26.
Zurück zum Zitat Vimalachandran D, Greenhalf W, Thompson C, et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 2005; 65:3218–25.PubMed Vimalachandran D, Greenhalf W, Thompson C, et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 2005; 65:3218–25.PubMed
27.
Zurück zum Zitat Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J 2001; 7:251–8.PubMed Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J 2001; 7:251–8.PubMed
28.
Zurück zum Zitat Ebert M, Yokoyama M, Friess H, et al. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 1995; 62:529–35.PubMedCrossRef Ebert M, Yokoyama M, Friess H, et al. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 1995; 62:529–35.PubMedCrossRef
29.
Zurück zum Zitat Friess H, Yamanaka Y, Büchler M. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993; 53:2704–7.PubMed Friess H, Yamanaka Y, Büchler M. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993; 53:2704–7.PubMed
30.
Zurück zum Zitat Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92:1300–4.PubMed Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92:1300–4.PubMed
31.
Zurück zum Zitat Zhu P, Martin E, Mengwasser J, Schlag P, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorogenesis. Cancer Cell 2004; 5:455–63.PubMedCrossRef Zhu P, Martin E, Mengwasser J, Schlag P, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorogenesis. Cancer Cell 2004; 5:455–63.PubMedCrossRef
32.
Zurück zum Zitat Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006; 281:13548–58.PubMedCrossRef Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006; 281:13548–58.PubMedCrossRef
33.
Zurück zum Zitat Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62:4041–7.PubMed Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62:4041–7.PubMed
34.
Zurück zum Zitat Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003; 309:558–66.PubMedCrossRef Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003; 309:558–66.PubMedCrossRef
35.
Zurück zum Zitat Ouaissi M, Ouaissi A. Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2006; 13474:1–10.CrossRef Ouaissi M, Ouaissi A. Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2006; 13474:1–10.CrossRef
36.
Zurück zum Zitat Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of the histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84–90.PubMedCrossRef Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of the histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84–90.PubMedCrossRef
37.
Zurück zum Zitat Dokmanovic M, Perez G, Xu W, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007; 6:2525–34.PubMedCrossRef Dokmanovic M, Perez G, Xu W, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007; 6:2525–34.PubMedCrossRef
38.
Zurück zum Zitat Mottet D, Bellahcène A, Pirotte S. HDAC7 silencing alters endothelial cell migration, a key step in angiogenesis. Cir Res 2007; 18:1794–801. Mottet D, Bellahcène A, Pirotte S. HDAC7 silencing alters endothelial cell migration, a key step in angiogenesis. Cir Res 2007; 18:1794–801.
39.
Zurück zum Zitat Dequiedt F, Kasler H, Fischle W, et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003:18:687–98.PubMedCrossRef Dequiedt F, Kasler H, Fischle W, et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003:18:687–98.PubMedCrossRef
40.
Zurück zum Zitat Kao HY, Verdel A, Tsai CC, et al. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem 2001; 276:47496–507.PubMedCrossRef Kao HY, Verdel A, Tsai CC, et al. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem 2001; 276:47496–507.PubMedCrossRef
41.
Zurück zum Zitat Parra M, Kasler H, McKinsey TA, et al. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem 2005; 280:13762–70.PubMedCrossRef Parra M, Kasler H, McKinsey TA, et al. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem 2005; 280:13762–70.PubMedCrossRef
42.
Zurück zum Zitat Sener S, Frengen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 1999; 189:1–7.PubMedCrossRef Sener S, Frengen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 1999; 189:1–7.PubMedCrossRef
Metadaten
Titel
High Histone Deacetylase 7 (HDAC7) Expression Is Significantly Associated with Adenocarcinomas of the Pancreas
verfasst von
Mehdi Ouaïssi, MD
Igor Sielezneff, MD
Ricardo Silvestre, PhD
Bernard Sastre, MD
Jean-Paul Bernard, MD, PhD
Joelle Simony Lafontaine, MD, PhD
Marie José Payan, MD, PhD
Laetitia Dahan, MD
Nicolas Pirrò, MD
Jean François Seitz, MD, PhD
Eric Mas, PhD
Dominique Lombardo, PhD
Ali Ouaissi, PhD
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9940-z

Weitere Artikel der Ausgabe 8/2008

Annals of Surgical Oncology 8/2008 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.